Delving into the Latest Updates on BMS-986308 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

KCNJ1

Mechanism

KCNJ1 inhibitors(potassium inwardly rectifying channel subfamily J member 1 inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Heart Failure

Inactive Indication-

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC24H25N7O2

InChIKeyNRCYDDLRPFXMNA-NYHFZMIOSA-N

CAS Registry2254333-97-4

Author: Govindrajan, Arun ; Wexler, Ruth R ; Kamble, Shyam ; Bora, Rajesh Onkardas ; Gulia, Jyoti ; Gunaga, Prashantha ; Rajugowda, Nagendra ; Sivaprasad Lvj, Sankara ; Lentz, Kimberley A ; Kole, Prashant ; Bhide, Rajeev ; Levesque, Paul C ; Priestley, E Scott ; Soleman, Sharif I ; Mathur, Arvind ; Akuthota, Nagarjuna ; Chacko, Silvi ; Godesi, Sreenivasulu ; Govindrajulu, Kavitha ; Sivaraman, Aneesh ; Rao, Prasanna ; Thatipamula, Rajendra Prasad ; Gordon, David A ; Yadav, Navnath ; Panda, Manoranjan ; Richter, Jeremy M ; Gupta, Anuradha ; Ramarao, Manjunath ; Sridhar, Srikanth ; Kaspady, Mahammed ; Dokania, Manoj

Recent literature reports highlight the importance of the renal outer medullary potassium (ROMK) channel in renal sodium and potassium homeostasis and emphasize the potential impact that ROMK inhibitors could have as a novel mechanism diuretic in heart failure patients. A series of piperazine-based ROMK inhibitors were designed and optimized to achieve excellent ROMK potency, hERG selectivity, and ADME properties, which led to the identification of compound 28 (BMS-986308). BMS-986308 demonstrated efficacy in the volume-loaded rat diuresis model as well as promising in vitro and in vivo profiles and was therefore advanced to clinical development.

100 Deals associated with BMS-986308

Login to view more data